These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33495184)

  • 21. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
    Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
    Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Roy T; An JB; Doucette K; Chappell AM; Vesole DH
    Leuk Lymphoma; 2022 Mar; 63(3):759-761. PubMed ID: 35076333
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.
    Mohan V; Jain S; Naithani R
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31152. PubMed ID: 38953139
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
    Yoshida T; Ri M; Fujinami H; Oshima Y; Tachita T; Marumo Y; Sasaki H; Kinoshita S; Totani H; Narita T; Masaki A; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2019 Aug; 110(2):228-236. PubMed ID: 31119611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
    Palazzo G
    Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
    Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
    Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 31. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
    Nalghranyan S; Singh AP; Schinke C
    Am J Hematol; 2020 Feb; 95(2):E34-E35. PubMed ID: 31709578
    [No Abstract]   [Full Text] [Related]  

  • 32. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
    Kazandjian D; Korde N; Mailankody S; Hill E; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2018 Dec; 4(12):1781-1783. PubMed ID: 30477009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
    Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
    Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
    [No Abstract]   [Full Text] [Related]  

  • 34. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 36. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
    Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.
    Dima D; Orland M; Ullah F; Anwer F; Mazzoni S; Raza S; Chaulagain CP; Samaras C; Valent J; Williams L; Khouri J
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):857-860. PubMed ID: 37558531
    [No Abstract]   [Full Text] [Related]  

  • 39. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
    Hampel PJ; Parikh SA; Call TG; Shah MV; Bennani NN; Al-Kali A; Rabe KG; Wang Y; Muchtar E; Leis JF; Kenderian SS; Koehler AB; Schwager SM; Slager SL; Kay NE; Hanson CA; Van Dyke DL; Shi M; Ding W
    Blood Cancer J; 2021 Mar; 11(3):47. PubMed ID: 33654067
    [No Abstract]   [Full Text] [Related]  

  • 40. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.